The AI that sees
what white light
misses.

cysto.ai is AI software that works with your existing cystoscopy setup to detect carcinoma in situ in real time during white light cystoscopy. No new hardware. No secondary procedure. No workflow disruption.

30–80%
CIS miss rate
600K
Annual US surveillance scopes
De Novo
FDA pathway
Request Site Partnership See the Technology
Bladder Map
CIS, 0.87
DETECTION ACTIVE · 30fps
Confidence
0.87
Frame
0847
Coverage
71%
Flags
2
AI ON
REC
1080p
Artistic rendering, not actual patient data
Regulatory pathway
FDA De Novo
Classification
CADe / CADx System
Hardware
Works with your existing cystoscopy setup.
The Clinical Problem

CIS is the hardest
cancer to catch.

Carcinoma in situ of the bladder is the most aggressive non-muscle-invasive bladder cancer. It is flat, non-papillary, and visually subtle, easily mistaken for benign inflammation or normal bladder tissue under standard white light cystoscopy.

White light is used in the vast majority of cystoscopies globally. Enhanced cystoscopy, such as blue light cystoscopy, improves detection but requires significant capital investment in dedicated hardware and involves a secondary invasive procedure, including instillation of a photosensitizing agent into the bladder before the examination. As a result, enhanced cystoscopy is unavailable at most practices where bladder cancer surveillance occurs.

Missed CIS has serious consequences. Left undetected, CIS advances to muscle-invasive disease in 40–83% of cases, requiring radical surgery. Bladder cancer has the highest lifetime treatment cost of any solid tumor in the United States, ranging from $200,000 to over $1 million per patient, driven by the relentless surveillance burden and high recurrence rates that follow a missed or delayed diagnosis.

30–80%
CIS miss rate under white light cystoscopy, even among expert urologists
$200K–$1M
Highest lifetime treatment cost of any solid tumor. Bladder cancer's recurrence rate means patients require surveillance cystoscopies every 3–6 months for life.
40–83%
Untreated CIS that progresses to muscle-invasive disease, depending on grade and follow-up interval
50–70%
Bladder cancer recurrence rate within 5 years, highest recurrence of any solid tumor
The Technology

What cysto.ai
does.

cysto.ai adds AI-powered CIS detection to standard white light cystoscopy, the equipment you already use in the office and the OR. It assists with real-time clinical decision making during the procedure, maps the bladder after each visit, and tracks changes over time.

Real-time detection

AI-Assisted Decision Making

During the procedure, a real-time heatmap highlights regions of interest associated with CIS on a secondary monitor adjacent to the physician's primary display. The system flags suspicious areas as the scope moves, giving the urologist actionable information at the point of care. Runs on an edge device at 30fps with no interruption to clinical workflow.

Post-procedure mapping

Spatial Reconstruction

After each procedure, the system automatically generates a spatially reconstructed map of the bladder from the cystoscopy video. The map shows scope coverage, AI detection locations, physician-flagged moments, and biopsy sites, all pinned to anatomical coordinates. A single image that captures the entire procedure. Currently in active development as part of the clinical trial.

Longitudinal tracking

Visit-to-Visit Comparison

On our development roadmap: the system will compare bladder maps across surveillance visits to detect change over time, giving urologists an objective spatial record of how each region has evolved between procedures. No other system provides this capability today. Building it is the goal.

Bladder Procedure Map

Every procedure,
mapped.

Generated automatically from procedure video. No additional steps required from the physician or coordinator. Unlike enhanced cystoscopy, no photosensitizing agent or secondary procedure is needed. Currently under active development as part of our clinical trial program.

Scope coverage map
Which regions were visualized, for how long, and in what sequence. Identifies under-examined zones.
AI detection events
Where the AI flagged regions of interest, pinned to anatomical location rather than just a frame timestamp.
Biopsy site record
Anatomical position of each biopsy captured at the moment of procedure. Replaces free-text location notes with a reproducible spatial record.
DOME L. LAT R. LAT POST CIS 0.87 BX AI DETECTION BIOPSY SITE Artistic rendering, in development
Hardware Setup

Works with your
existing setup.

Compatible with all major cystoscopy towers. No modification to existing equipment. No secondary invasive procedure. The device operates in a pass-through configuration, so your existing display and workflow are completely unaffected. Installation takes approximately two hours with no equipment downtime.

Cystoscope
VIDEO OUT
Video
Processor
HDMI
cysto.ai
intelligent cystoscopy
cysto.ai
Device
HDMI
AI ON
CIS 0.87
30fps
Overlay
Monitor
Artistic rendering of investigational device
Global Clinical Network

Building across
four continents.

cysto.ai is establishing a multi-site clinical network spanning the United States, Europe, the Middle East, and Asia-Pacific, building the only pathology-correlated, spatially-annotated cystoscopy dataset in the world.

North America · Europe · Middle East · Asia-Pacific

Press

In the news.

AUA Innovation Nexus 2026
cysto.ai Selected as Seed Stage Showcase Presenter
Etta.io, DBA cysto.ai, has been selected to present at the 2026 AUA Innovation Nexus Forum Showcase in Washington DC, joining a curated cohort of seed-stage urology companies presenting to leading urologists, clinicians, and industry stakeholders.
View on AUA Innovation Nexus →
Team

Built by people
who care.

Charu Singhal
Charu Singhal
Co-Founder & CEO
Charu holds a graduate degree in data science, with a capstone in ML-based breast cancer tumor classification that sparked her focus on AI diagnostics. Before cysto.ai, she built machine learning systems for the State of Illinois and City of Chicago spanning public health, foster care, and opioid tracking. She leads all AI development, clinical partnerships, and product strategy at Etta.io. Outside of work she plays harp and teaches English in refugee communities.
Dr. Nitin Yerram Dr. Nitin Yerram
Co-Founder & CMO
Dr. Yerram is Director of Urologic Research and Co-Director of Urologic Oncology at Hackensack Meridian Health Network, and a prolific researcher and surgeon in urologic oncology. At the National Cancer Institute, he led development of an AI tool to grade prostate cancer pathology slides, working across clinical, data science, and research teams, a direct precursor to the AI diagnostic field cysto.ai operates in. He leads clinical trial strategy, FDA clearance pathways, reimbursement, and health system integration at Etta.io. In his spare time he is an avid student of space exploration and hopes to travel to space one day.
Dr. Michael Ahdoot Dr. Michael Ahdoot
Advisor
Dr. Ahdoot is a urologic oncologist at Cedars-Sinai Hospital in Los Angeles, specializing in prostate, kidney, and bladder cancers. He is an innovator in the field, holding patents for both orthopedic and urologic devices, and is actively involved in clinical trials and medical device development. His research has been featured at international conferences and in the New England Journal of Medicine.
Dr. Jason Cohen Dr. Jason Cohen
Advisor
Dr. Cohen is a board-certified urologist focused on the intersection of urology and technology. Trained at Johns Hopkins University School of Medicine and Northwestern University, he brings deep expertise in minimally invasive and endoscopic urologic surgery. Having practiced in rural and resource-constrained settings, he has a strong appreciation for the practical challenges of delivering high-quality care with limited resources, and the opportunities for technology to expand access and improve efficiency.
Dr. Reagan Anderson Dr. Reagan Anderson
Advisor
Dr. Anderson is a Board Certified Dermatologist and Fellow of the American Society of Mohs Surgeons, specializing in general dermatology and Mohs Micrographic Surgery for skin cancer. He is one of approximately 40 Mohs surgeons in the US to hold the American Osteopathic Board of Dermatology Certificate of Added Qualification in Mohs Micrographic Surgery.
Get Involved

Let's build this
together.

We are actively enrolling investigational sites and building strategic partnerships. If you are a urologist, hospital administrator, or potential collaborator, we would like to speak with you.

Participating sites receive the full hardware kit, installation support, and early access to each new capability as the platform develops. There is no cost to the site.

Become a Clinical Site General Inquiry
Etta.io also develops AI solutions for dermatology. Get in touch →